Recon: Sanofi CEO promises access to COVID-19 vaccine after French backlash; Japan says remdesivir in use at hospitals

• Trump Taps Ex-Glaxo Official and General to Lead Vaccine Race (Bloomberg) (Reuters) (Politico)
• Trump mobilizing US military to deliver coronavirus vaccine (Reuters)
• Trump administration fires back at ousted vaccine expert as he testifies on his role in US coronavirus response (STAT) (WSJ)
• Ousted vaccine chief: 'Our window of opportunity is closing' (Politico 1, 2)
• A Trump Official Tried to Fast-Track Funding for His Friend’s Unproven COVID-19 “Treatment,” Whistleblower Says (ProPublica)
• Accuracy of rapid coronavirus test called into question by NYU study (Politico) (Reuters) (NYTimes)
• US to tell doctors to report cases of COVID-19 inflammatory syndrome in kids (Reuters 1, 2)
• Sanofi gets priority FDA review for sutimlimab product (Reuters)
• Amgen’s KRAS-blocking drug shows small improvement in colon cancer response (STAT) (Endpoints)

• 'This virus may never go away,' WHO says (Reuters)
• Sanofi CEO pledges virus vaccine for all after French backlash (Reuters) (Financial Times) (Endpoints)
• Why vaccine ‘nationalism’ could slow coronavirus fight (Financial Times)
• China calls US accusation of hacking in COVID-19 research "slander" (Reuters)
• Japan says drugmaker Gilead's COVID-19 treatment remdesivir now in use in hospitals (Reuters)
• Health groups ask India to rescind Gilead's patents for COVID-19 drug remdesivir (Reuters)
• CureVac's coronavirus vaccine candidate triggered immune response in animal tests (Reuters)
• MHLW to Accept Applications for COVID-19 Treatments Without Clinical Trial Data; Avigan, Alvesco, Futhan Might Be Eligible (PharmaJapan)
• Takeda says coronavirus treatment trial using recovered patients' blood could start in July (Reuters)
• UK follows EU, US to approve Roche COVID-19 antibody tests (Reuters)
• DiaSorin gets Canada's approval for sale of COVID-19 antibody tests (Reuters)
• Roche’s novel checkpoint inhibitor delivers mixed results in new lung cancer study (STAT) (BioPharmaDive) (Endpoints)
• Novo Nordisk’s first semaglutide obesity trial hits the mark (PMLive)
• Boehringer Ingelheim Acquires Northern Biologics’ Preclinical Pipeline (Xconomy) (Press)
• Israel approves medical cannabis exports (Reuters)

• World Health Assembly draft resolution boosts access to Covid-19 medicines (STAT)
• Abivax to Begin Testing Experimental Colitis Drug for Covid-19 (Bloomberg)
• Dozens of coronavirus drugs are in development — what happens next? (Nature)
• Gilead should ditch remdesivir and focus on its simpler and safer ancestor (STAT)
• Sitting in a freezer for years, potential SARS vaccine now ready for coronavirus trial (USA Today)
• Coronavirus surveillance program in King County put on hold because of FDA concerns (Seattle Times)
• Trucks used to store bodies amid pandemic can haul food again, FDA says (Miami Herald)
• Eisai Resurrects Eritoran as Potential COVID-19 Treatment, Eyes Trial Launch Next Month (PharmaJapan)
• India to test four drugs as part of WHO trial (Economic Times)
• LabCorp to make COVID-19 testing services available at workplaces (Reuters)
• Remote digital monitoring in clinical trials in the time of COVID-19 (Nature)
• BMJ, Nature warn against 'sabotaging' COVID-19 response with poor and 'chaotic' trials (Fierce)
• China's BGI gets Australian foothold through mass coronavirus test delivery (Reuters)
• Italy launches blood tests to investigate who has had COVID-19 (Reuters)
• Spanish antibody study points to 5% of population affected by coronavirus (Reuters)
• Only 4.4% of French population infected by coronavirus: Pasteur institute (Reuters)
• Brazil passes France in coronavirus cases to become 6th worst-hit country (Reuters)
• Moscow says it ascribed over 60% of coronavirus deaths in April to other causes (Reuters)
• Coronavirus (COVID-19) Update: Daily Roundup May 13, 2020 (FDA)

• BIO gets a new chief lobbyist to face off against the growing ranks of critics in Congress (Endpoints)
• Reprogrammed skin cells inserted in brain help Parkinson's patient regain function: study (Reuters) (STAT)
• J&J myeloma data heat up cell therapy battle (BioPharmaDive)
• ASCO: Off-the-shelf CAR-T pioneer Allogene shows early hints of efficacy in lymphoma (Fierce) (BioPharmaDive) (Endpoints)
• Bristol Myers Squibb spells out OS benefit of Opdivo/Yervoy combo plus 'limited' chemotherapy — is it enough to change practice? (Endpoints) (Fierce)
• BCMA rival to bluebird, Bristol Myers files for $100M IPO as the frontrunners stumble in a race to the finish line (Endpoints)
• Days after rapid FDA approval, Lilly and Blueprint go head-to-head again at ASCO (Endpoints)
• MacroGenics chief Scott Koenig details the upbeat cancer drug data from 2 programs that drove a big spike in their share price (Endpoints)
• ASCO: Pfizer, Astellas show Xtandi helps early prostate cancer patients live longer (Fierce)
• ASCO: Arvinas unveils first-in-human data for novel protein degrader in prostate cancer (Fierce)
• ASCO: Is the PD-1 target behind Keytruda's small-cell miss? Merck exec says no (Fierce)
• Avrobio posts 22-month update on Fabry gene therapy trial (Fierce)
• ‘Good’ bacteria could help fight a common vaginal infection, new data show (STAT)
• European Commission Approves Adcetris For Treatment Of Systemic Anaplastic Large Cell Lymphoma (Reuters) (Press)
• How the pandemic helped secure a rare cancer drug for Menarini (Endpoints)
• Amazon, Berkshire Hathaway and J.P. Morgan’s joint venture to revamp health care loses its CEO (CNBC)
• Continuous Manufacturing Back In Second Act (Pink Sheet)
• Gedeon Richter Chief Makes Biosimilars Prophecy (Pink Sheet)
• Back To Normal? US FDA Schedules In-Person Meeting But Pauses Non-COVID Guidance Development (Pink Sheet)

• To screen COVID-19 patients for heart problems, FDA clears several ultrasound, AI devices from Philips, Eko, Caption Health (Fierce)
• EFTA countries and Russia introduce COVID-19 policy changes (Emergo)
• Hims & Hers, Vault Health now sell FDA-authorized home COVID-19 tests via telehealth (MobiHealthNews)
• Smiths Medical acquires Access Scientific (MassDevice)
• FDA clears ophthalmic camera from Optina Diagnostics (MassDevice)
• Nevro Senza Omnia SCS wins CE Mark (MassDevice)

• State Supreme Court Overturns The Stay-At-Home Order In Wisconsin (NPR)
• COVID-19 Underscores Diagnostic Patent Eligibility Problems (Law360)
• Natera, Illumina Ink Deal To End Row Over DNA Testing IP (Law360)
• CVS Unit To Pay $15M Over 'Improper' Opioid Dispensing (Law360) (STAT)
• Don't Bet On Aug. Trial In CVS Drug-Pricing Suit, Judge Says (Law360)
• MDL Won't Stop PTAB From Reviewing Merck Diabetes Patent (Law360)
• How to manage temporary GDP process changes and risks through the COVID-19 pandemic (MHRA)